Stevanato Group missed Q4 earnings slightly but raised 2026 guidance, citing strong demand for high-value drug packaging.

Stevanato Group reported Q4 2025 earnings on March 4, 2026, with adjusted EPS of €0.17, slightly below the €0.20 consensus, though revenue rose 4.8% year-over-year. Full-year 2025 revenue grew 7% (9% at constant currency), driven by strong demand for high-value pharmaceutical packaging, particularly GLP-1 therapies and biologics. The company raised its 2026 EPS guidance to €0.690–0.730, projecting revenue of approximately €1.5 billion. Despite a modest EPS miss, Stevanato highlighted record revenue from high-value solutions, expanded margins, and ongoing capacity investments. The stock surged on the news, reflecting investor confidence in its long-term growth outlook.